Salute e Benessere

HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology…

Accepted as a late-breaker, the oral presentation by Dr. Jörn M Schattenberg, Professor of Medicine and Director of the Department of Medicine II at the University Medical Center Homburg and the University of the Saarland Germany, compares the specific fibrotic features identified by qFibrosis with ordinal scoring and NITs in their correlation to fibrosis progression. Commenting on the significance of this work, Dr. Schattenberg stated, "There is a need to improve the methods we are…
PR Newswire
03/06/2024

Evosep Unveils Groundbreaking Innovations in Scalable Proteomics Workflows at…

Fully Automated Workflows: Capable of processing over 500 plasma samples per day, these workflows are designed to maximize efficiency and throughput while minimizing manual labor and potential for error, particularly benefiting drug discovery and translational research. Fully Automated Workflows:Capable of processing over 500 plasma samples per day, these workflows are designed to maximize efficiency and throughput while minimizing manual labor and potential for error, particularly...
PR Newswire
03/06/2024

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA…

CelluTx's Chief Executive Officer, Maurits Geerlings said, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven capabilities and the highest commitment to its customers, which has been fundamental to our partnering with BioCina." CelluTx's Chief Executive Officer,Maurits Geerlingssaid, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina…
PR Newswire
03/06/2024

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet…

Saint-Herblain (France), June 3, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal,The Lancet Infectious Diseases. These trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the current pivotal Phase 3 trial, 'Vaccine Against Lyme for Outdoor Recreationists'...
Nasdaq GlobeNewswire
03/06/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 3 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
03/06/2024

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer…

VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are diagnosed at advanced stages, which are significantly harder to treat. A new study published in the journal Cell Genomics demonstrates that researchers have identified key protein biomarkers for early detection of…
PR Newswire
03/06/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from May 27, 2024 to May 31, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
03/06/2024

BioPharmaSpec Announces Major Investments in Mass Spectrometry and Related…

The state-of-the-art instrumentation will support and accelerate BioPharmaSpec's clients' efforts in successful biologics product development BioPharmaSpec ”), the leading global Contract Research Organization (CRO) for discovery and preclinical characterization of biopharmaceuticals, has made major new investments in instrumentation, including top-of-the-range Mass Spectrometers, to support its clients in their product development goals. On June 1st, 2024, BioPharmaSpec announced that it...
Nasdaq GlobeNewswire
03/06/2024

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging…

Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, presented in a rapid oral session at 2024 ASCO® Annual MeetingHNSCC is the sixth most common cancer worldwide, with incidence rates expected to increase 30% by 2030iGenmab A/S(Nasdaq:GMAB)announced today that data from the Phase 2 innovaTV 207 trial ( NCT03485209 )...
Nasdaq GlobeNewswire
03/06/2024

Waters Sets New Standards for High Resolution Performance and Speed with Xevo…

"Understanding complex diseases requires analysis of thousands of samples from large human cohorts to provide statistically valid studies. This puts increased pressure on drug discovery scientists to deliver high-quality data in shorter run times," said Dr. Udit Batra, CEO and President of Waters Corporation. "The Xevo MRT mass spectrometer is a next generation QTof built from the ground up to address this unmet need, delivering high resolution and speed without compromising…
PR Newswire
03/06/2024

Zero Candida Announces its Intent to Complete Listing of its Shares on the TSX…

ZC is a private FemTech technology company incorporated under the corporate laws of the State of Israel. ZC is developing an AI smart tampon-like device based on AI on a therapeutic light source with a selected wave-length and intensity that can treat the Candida fungus with successfully of 99.999% an POC. Vulvo-Vaginal Candidiasis ("VVC") affects about 75% of women globally, each year 138 million women are affected world-wide and 492 million over their lifetime. Recurrent VVC (4 or…
PR Newswire
03/06/2024

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial…

Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patientsFindings further confirm and validate the precision and predictive power of Evaxion's AI vaccine target discovery and design platform, AI-Immunology™ COPENHAGEN, Denmark, June03, 2024(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Nasdaq GlobeNewswire
03/06/2024

MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest…

Additionally, Dr. Marie-Laure Yaspo from Germany's ALACRIS Theranostics shared insights into the quality upgrade made possible by the new StandardMPS 2.0 (SM 2.0) sequencing chemistry, first announced during AGBT 2024 in February. Enabled by updated sequencing reagents and software, SM 2.0 delivers an impressive proportion of ≥85% for base quality scores reaching or exceeding Q40 during sequencing on MGI's DNBSEQTM platform. Continuous improvement of the sequencing chemistry, without…
PR Newswire
03/06/2024

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation…

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June03, 2024(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading...
Nasdaq GlobeNewswire
03/06/2024

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved…

— Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing — — Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing — DUBLIN,June 3, 2024/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily...
PR Newswire
03/06/2024

SHEIN Launches SHEIN Exchange Resale Platform in Europe and the United Kingdom

SHEIN Exchange, an integrated online peer-to-peer resale platform to buy and sell previously owned SHEIN products, is launching across three of SHEIN's markets in phases. Users in France can now access the SHEIN Exchange platform, with the resale platform to be made available in the UK and Germany in subsequent phases. SHEIN Exchange, an integrated online peer-to-peer resale platform to buy and sell previously owned SHEIN products, is launching across three of SHEIN's markets in phases...
PR Newswire
03/06/2024

Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by…

Key Takeaways from the Bispecifics/Trispecifics Market Report Key Takeaways from the Bispecifics/Trispecifics Market Report Discover which therapies are expected to grab the major bispecific/trispecific market share @Bispecifics/Trispecifics Market Report Bispecifics/Trispecifics Overview Bispecific antibodies are designed to simultaneously attach to two distinct epitopes or antigens, offering a promising avenue for enhancing target specificity. This dual-binding capability...
PR Newswire
03/06/2024

MuscleBlaze BIOZORB Whey Protein redefines fitness in UAE with Cutting-edge…

MuscleBlaze BIOZORB whey protein range transcends conventional supplements with its U.S. Patent published formulation. This underscores MuscleBlaze's commitment to advancing the boundaries of nutritional science. MuscleBlaze BIOZORB whey protein range transcends conventional supplements with its U.S. Patent published formulation. This underscores MuscleBlaze's commitment to advancing the boundaries of nutritional science. Maximizing Performance: Clinically Tested 50% Enhanced Protein...
PR Newswire
03/06/2024

STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA…

CAMBRIDGE, England, June 3, 2024 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that interim Phase 1 clinical data from its first-in-class lead product, STC-15, was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, US. CAMBRIDGE, England,June 3, 2024/PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company...
PR Newswire
03/06/2024

Orion is developing the Finnish life science industry in a unique collaboration…

ORION CORPORATIONPRESS RELEASE03 June 2024 at 09.30 EEST Orion is developing the Finnish life science industry in a unique collaboration project Orion is participating in a project led by the University of Turku for which Business Finland recently granted 11.7M€ funding. The project seeks to enhance advanced pharmaceutical and life science manufacturing in Finland. The LifeFactFuture project combines world-class-excellence of Finnish life science companies, technology...
Nasdaq GlobeNewswire
03/06/2024

RAMSAY SANTE : Agreement reached with the government on funding of private…

PRESS RELEASEParis, 3 June 2024 Agreement reached with the government on fundingof private hospitals After two months of mass mobilisation and intense discussions with the government, a compromise was reached on 24 May 2024 between the government and the Federation of private clinics and hospitals, set out in a letter of commitment from the delegate Ministry of Health.The Government's commitment includes, first and foremost,the principle of equal treatment between the private...
Nasdaq GlobeNewswire
03/06/2024

Augnito Appoints Hamza Moftah as Associate Vice President of Sales to Accelerate…

Rustom Lawyer, Co-Founder & CEO of Augnito, expressed his enthusiasm for Hamza's appointment, stating, "The GCC region is of paramount importance to us as AI innovators. Hamza's deep understanding of the digital health landscape and his ability to drive impactful change will be instrumental in our mission to empower clinicians, ensure the highest levels of quality and precision in documentation and administration, and improve patient outcomes in the region." Rustom Lawyer…
PR Newswire
03/06/2024

Pharming Group to participate in June investor conferences

Leiden, the Netherlands, June 3, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New York, USA, June 5-6, 2024Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News”...
Nasdaq GlobeNewswire
03/06/2024

Number of voting rights as of May 31, 2024

Nicox SA Société anonyme with a registered capital of € 502,996.94 Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot R.C.S. ANTIBES 403.942.642 On June 3 rd, 2024, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article 223-16 of the General Regulation of the AMF) Market: Euronext Growth ParisISIN Code: FR0013018124 Website:www.nicox.com As of May 31, 2024...
Nasdaq GlobeNewswire
03/06/2024
Altri  Comunicati